Imperial showcases innovation and outreach to the UK’s Chief Scientific Adviser
Podcast: Smart tattoos, the future of the NHS and next-generation vaccines
Aspirin cuts heart attack risk but increases chance of dangerous bleeding
Translating basic science from molecular and cellular biology to clinical studies in patients with COPD and severe asthma.
Uniting the related areas of Chronic Respiratory Failure and Sleep and Ventilation to improve patient care through research.
New research section headed by Professor Stuart Elborn.
Studying disease mechanisms in airway inflammatory diseases, with specific interest in exacerbations and the role of viral and bacterial infections.
Designing and developing gene therapy treatments for cystic fibrosis using a bench to bedside strategy.
Applying cutting-edge genomic technologies to the study of lung diseases, and related disorders, to identifying important genes that predispose to illness and develop treatment based on these.
Understand host immune response to tuberculosis to improve clinical management of patients and tuberculosis control at the global level.
Understanding how developmental, environmental or medical factors contribute to adult lung disease and injury to discover novel treatments to repair or induce regeneration.
Researching the physiology and pathology of normal heart and lung function and associated diseases.
Developing new treatment strategies for the treatment of asthma, COPD and cough together with investigation of pulmonary inflammation and lung disease caused by inhaled airborne particles.
Employing epidemiological and environmental methods to understand the determinants of respiratory health.
Furthering our understanding of respiratory infection by RSV and flu to define protective responses to prevent immune system over reaction and damage.